FDA lifts clinical hold on Cellectis' CAR T candidate

Cellectis S.A. (Euronext:ALCLS; NASDAQ:CLLS) said late Monday that FDA lifted a clinical hold on Phase I testing of its chimeric antigen receptor (CAR) T cell candidate UCART123 to treat acute myelogenous leukemia

Read the full 324 word article

User Sign In